Trial Profile

A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RTX-134 (Primary)
Indications Phenylketonuria
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
Sponsors Rubius Therapeutics [CEASED]

Most Recent Events

05 Dec 2022 Status changed from active, no longer recruiting to discontinued.
07 Dec 2020 Planned End Date changed from 1 May 2020 to 1 Mar 2035.
07 Dec 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Mar 2035.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com